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Abstract
Introduction: Congenital muscular dystrophy is a distinct group of diseases presenting with weakness in infancy or
childhood and no current therapy. One form, MDC1A, is the result of laminin alpha-2 deficiency and results in significant
weakness, respiratory insufficiency and early death. Modification of apoptosis is one potential pathway for therapy in these
patients.
Methods: dy2J mice were treated with vehicle, 0.1 mg/kg or 1 mg/kg of omigapil daily via oral gavage over 17.5 weeks.
Untreated age matched BL6 mice were used as controls. Functional, behavioral and histological measurements were
collected.
Results: dy2J mice treated with omigapil showed improved respiratory rates compared to vehicle treated dy2J mice (396 to
402 vs. 371 breaths per minute, p,0.03) and similar to control mice. There were no statistical differences in normalized
forelimb grip strength between dy2J and controls at baseline or after 17.5 weeks and no significant differences seen among
the dy2J treatment groups. At 30–33 weeks of age, dy2J mice treated with 0.1 mg/kg omigapil showed significantly more
movement time and less rest time compared to vehicle treated. dy2J mice showed normal cardiac systolic function
throughout the trial. dy2J mice had significantly lower hindlimb maximal (p,0.001) and specific force (p,0.002) compared
to the control group at the end of the trial. There were no statistically significant differences in maximal or specific force
among treatments. dy2J mice treated with 0.1 mg/kg/day omigapil showed decreased percent fibrosis in both
gastrocnemius (p,0.03) and diaphragm (p,0.001) compared to vehicle, and in diaphragm (p,0.013) when compared
to 1 mg/kg/day omigapil treated mice. Omigapil treated dy2J mice demonstrated decreased apoptosis.
Conclusion: Omigapil therapy (0.1 mg/kg) improved respiratory rate and decreased skeletal and respiratory muscle fibrosis
in dy2J mice. These results support a putative role for the use of omigapil in laminin deficient congenital muscular dystrophy
patients.
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Introduction
The congenital muscular dystrophies (CMDs) are a group of
heterogeneous pediatric neuromuscular diseases that present with
hypotonia, progressive scoliosis, contractures and respiratory
insufficiency. [1] Currently recognized as a group of distinct
diseases, the CMDs are a progressive and life limiting neuromus-
cular condition and there are currently no treatments available.
The CMDs develop early and progressive respiratory insufficien-
cy, with morbidity and mortality largely influenced by optimal
pulmonary management. MDC1A, one type of CMD, is caused
by defects in the laminin a2 gene (LAMA2) gene. [2] It is a severe
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and incapacitating disease with neonatal hypotonia, weakness,
white matter changes and early death. [3] Histopathological
analysis of these patients show significant muscle degeneration and
increased apoptosis. [4] There are two current mouse models of
laminin mutations used for preclinical studies, dyW and dy2J. The
dyW mouse model demonstrates a severe phenotype with poor
growth and early death due to absence of the laminin a2 protein.
[5] The dy2J model has a milder phenotype with a longer lifespan
due to the presence of a truncated laminin a2 protein. [6] Both
models display hindlimb paralysis related to demyelination and
dystrophic changes in the skeletal muscle.
Recognition and lack of treatment for CMD patients has
generated a need for further preclinical drug testing in CMD
mouse models. Miyagoe et al. (1997) described a LAMA2 deficient
mouse model (dy3K) with increased TUNEL positive nuclei in
degenerating skeletal muscles in LAMA2 knockout mice. [7]
Girgenrath et al. (2004) showed improved survival and myofiber
histology after applying anti-apoptotic breeding crosses. [8]
Dominov et al. (2005) also demonstrated increased growth and
survival in LAMA2 null dyW mice with over expression of the anti-
apoptotic protein BCL2. [9] Most recently, Erb et al. (2009)
demonstrated a role for the GADPH-Siah1-CBP/p300 apoptosis
pathway in dyW mice by demonstrating a beneficial effect on
histology, locomotion, skeletal deformities, weight and survival in
mice treated with omigapil. [10] This drug was also effective in a
mouse model of progressive motor neuropathy. [11] Omigapil
(TCH346) was used previously in clinical trials for Parkinson
disease and amyotrophic lateral sclerosis where apoptosis is
considered a key pathogenic pathway based on animal models.
[12,13] While neither trial demonstrated a clinical effect in these
diseases, omigapil was well tolerated and may benefit patients with
other neuromuscular diseases.
In this study, a phenotypic analysis of preclinical outcomes
measures was performed in the dy2J mouse model with truncated
laminin a2 protein. These mice were treated with the anti-
apoptotic agent omigapil at two doses to assess effects on outcome
measures. dy2J mice demonstrated functional and histological
improvements and these results provide preclinical data for future
putative clinical trials in CMD patients.
Methods
Animals
The protocol was approved and all mice were handled
according to the local Institutional Animal Care and Use
Committee guidelines (DCVAMC #01079). Generally, homozy-
gous B6.WK-Lama2dy-2J/J (dy2J) and C57BL/6J (BL6) mice were
purchased from the Jackson Laboratory (Bar Harbor, MA). All
mice were housed in an individually vented cage system with a 12
hour light-dark cycle and received standard mouse chow and
purified water ad libitum. All mice were acclimated, first to the
room and then to different instruments for functional tests before
the trial. Functional data was collected in the morning hours over
a 2 week period. Mice were treated with omigapil (1 mg/kg/day
or 0.1 mg/kg/day) daily via oral gavage starting at 12 to 15 weeks
of age. Mice were treated for 10 weeks continuously and outcome
data collected. Mice received no omigapil for the following 4
weeks and outcome data was collected. Mice were then retreated
with omigapil for another 3.5 weeks and final measurements
obtained after 17.5 weeks.
Grip Strength Test
Grip strength was assessed using a grip strength meter consisting
of horizontal forelimb mesh and an angled hind limb mesh
(Columbus Instruments, Columbus OH) as described previously.
[14] For forelimb strength, the animals were held so that only the
forelimb paws grasped the flat mesh assembly and pulled back
until their grip was broken. Five successful forelimb strength
measurements within 2 minutes were recorded and the maximum
values of each day over 5 day period were used for analysis.
Open Field Activity (Digiscan)
Locomotor activity as measured using an open field digiscan
apparatus (Omnitech Electronics, Columbus, OH) as previously
described. [14] A total of 21 measurements per mouse including
horizontal activity, vertical activity, total distance, movement time
and rest time were recorded every 10 minutes for 1-hour as
described previously.[15–17].
Whole Body Plethysmography
The whole body plethysmography system (ADInstruments, St.
Paul, MN) utilized a custom mouse chamber developed by the
Research Instrument Shop at the University of Pennsylvania to
minimize dead space. Other components include the spirometer
(ML141), respiratory flow head (MLTL1) and the PowerLab 4/30
with LabChart software. The mouse was brought to the
measurement room 15 minutes before the start of the measure-
ment session to recover from the transportation and new
environment stresses. The spirometer was calibrated every time
the hardware was powered on to read in terms of flow (ml/s)
rather than pressure (mv).Calibration of the plethysmography with
1ml of air was injected into the animal chamber to correlate the
injected volume (ml) with the differential pressure (mv) measured
in the chamber by integration. A 700 ml/min flow of dry air
through the chambers was constantly delivered to avoid CO2 and
water accumulation and to maintain a constant temperature. The
mouse was weighed and placed into the mouse chamber first to
acclimate for 10 minutes then record the respiratory flow data for
15 minutes. For data analysis, we calculated the values for
respiratory rate using LabChart software.
High Frequency Echocardiography
Echocardiography (VisualSonics Vevo 770, Toronto, Canada)
was performed as detailed previously. [14] Mice were first
anesthetized with 5% isoflurane mixed with 100% oxygen at
0.6 L/min flow, then maintained under anesthesia with 1.5%
isoflurane/oxygen flow. A heating lamp was used to keep the heart
rate and temperature constant at physiological status. Heart rate,
aortic/pulmonary velocity, fractional shortening (FS), ejection
fraction (EF) and mitral valve (MV) E/A ratio were obtained for
cardiac function assessment. Qualitative and quantitative mea-
surements were made offline using analytic software.
In vitro Muscle Force Testing
In vitro muscle force testing (Servomotor/force transducer model
305B, Aurora Scientific, Ontario, Canada) was performed as
previously described. [18] Briefly, the extensor digitorum longus
(EDL) muscle from the right hindlimb was carefully dissected from
the mouse and placed in an in vitro bath filled with Ringer solution.
The maximal force generated by the muscle was measured at the
determined optimal length.
Histological Evaluations
Paraffin sections and H&E staining were performed by
Histoserv, Inc. (Germantown, MD). Ten non-overlapping repre-
sentative fields of the tissue were imaged under a light microscope
at an objective of 40X and a digital image obtained using
Omigapil Treatment in dy2J Mice
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computer software (Olympus C.A.S.T. Stereology System, Olym-
pus America Inc., Center Valley, PA). The digital images were
loaded into Image J (NIH) for counting total fiber, regenerated
fiber, fiber with centralized nuclei and percent centralized nuclei
fiber was calculated. [14] The measurements were averaged from
10 non-overlapping fields. Due to extensive areas of degenerating
fibers in dy2J mice, images of the gastrocnemius were also obtained
at 10X and used to determine percent area of degenerating fibers.
Areas of degeneration were outlined using Image J program and
compared to total tissue area for 10 non-overlapping areas. The
calculated areas were averaged and expressed as percent area of
degeneration. Apoptotic myonuclei were detected in frozen
sectioned tibialis anterior muscle by TACS 2 TdT-DAB labeling
(TUNEL) with use of the In Situ apoptosis detection kit (Trevigen,
Gaithersburg, MD). Each group had 4 samples for the TUNEL
assay. BL6 slides treated with TACS-Nuclease (Trevigen,
Gaithersburg, MD) were used as positive controls. Six non-
overlapping fields of the entire tissue section were imaged at 40X.
Only TUNEL- and Methyl Green-positive nuclei that were
located within muscle fibers were counted as apoptotic myonuclei.
Apoptotic myonuclei values were averaged and expressed as
percentage relative to the total number of myonuclei.
Quantification of Fibrosis
Paraffin sections of gastrocnemius and diaphragm tissue were
stained with picrosirius red by Histoserv, Inc. (Germantown, MD).
The tissues were magnified under a light microscope at an
objective of 1.25X and digital images obtained using computer
software (Olympus C.A.S.T. Stereology System, Olympus Amer-
ica Inc., Center Valley, PA). These digital images were processed
using Image J (NIH) with additional threshold color plug-ins to
process jpeg images. Pixels corresponding to the area stained in
red were normalized to the total pixel area of the tissue image and
the results were expressed as percent of collagen. [18].
Statistical Analysis
Normality of each quantitative measurement was assessed
using the Shapiro-Wilk normality test and those measurements
not meeting the normality assumption were analyzed with
nonparametric tests. Mean comparisons between treatment
groups were done at baseline (Table 1) and at 17.5 weeks
(Table 2) using analysis of variance (ANOVA). For those
ANOVA models showing a significant overall p-value (p,0.05),
post-hoc pair-wise linear tests were performed with the resulting
p-values adjusted for multiple testing using the Sidak method.
Median comparisons between treatment groups were done for
those non-normally distributed measures (open field activity)
using Kruskal-Wallis tests. For those tests showing a significant
p-value (p,0.05), post-hoc pair-wise linear tests were performed
using Wilcoxon rank sum tests with the resulting p-values
adjusted for multiple testing using the Sidak method. Histolog-
ical evaluations were compared between groups using poisson
regression for count data with group included as an indicator
variable. Measurements at 17.5 weeks were also evaluated as a
percentage of mean W/T values where percentage was
calculated as (individual values/mean of W/T group) * 100.
Median percentages were compared between three dy2J mice
groups using Kruskal-Wallis tests with post-hoc pairwise compar-
isons done with Wilcoxon rank sum tests and resulting p-values
adjusted using the Sidak method. The percentage of W/T could
not be calculated for several histological evaluations could due
to all W/T animals having a zero value. Nominal significance
was set at alpha= 0.05 and all analyses were performed using
Stata V 11 (College Station, TX).
Results
Phenotypic Differences Between dy2J Mice and C57BL6/J
Control Mice
Body and organ weights. At 12–15 weeks of age, dy2J mice
were significantly smaller than control mice (Table 1). From this
12–15 to 30–33 weeks of age, control mice increased their weight
by 20% and dy2J increased by only 10% (Table 2). dy2J mice had
consistently lower normalized tissue weights compared to controls
for the gastrocnemius, tibialis anterior and soleus. The heart and
spleen were slightly increased but not significantly different.
Behavioral assessment. dy2J mice had significantly lower
maximal forelimb grip strength when compared to the BL6
control mice at 12–15 and 30–33 weeks of age. However, when
normalized for body weight, there were no statistical differences.
Hindlimb grip strength was not performed since the hindlimbs
showed significant atrophy due to paralysis throughout the
duration of the study. There were no significant differences in
horizontal activity, total distance, movement time or rest time
between control and dy2J mice at 12–15 weeks of age, but dy2J
mice showed significantly decreased vertical activity. At 30–33
weeks of age, dy2J mice showed significantly decreased horizontal
activity, total distance, movement time, rest time and vertical
activity compared to controls.
Functional assessment. Lung function was assessed by
whole body plethysmography at 30–33 weeks of age. dy2J mice
showed significantly decreased respiratory rates compared to
control mice. There were no significant differences in cardiac
function between dy2J and control mice. Both strains showed
normal systolic function at 12–15 and 30–33 weeks of age.
However, dy2J mice had significantly increased heart rates
compared to control mice. dy2J mice had significantly lower
hindlimb EDL maximal and specific force when compared to the
control group at 30–33 weeks of age.
Longitudinal changes in selected outcome measures are shown
in Figure S1. Individual measures for selected outcomes and age of
measurement are shown in Figure S2.
Histological assessment. dy2J mice had significantly in-
creased percent fibrosis in the gastrocnemius and diaphragm when
compared to the BL6 control at 30–33 weeks of age. dy2J mice also
demonstrated significantly increased percent area of degenerating
fibers in the gastrocnemius and increased percent of centralized
nuclei per fiber in the gastrocnemius and diaphragm. (Figure 1).
TUNEL assay. In the tibialis anterior, there was a significant
increase in the percent TUNEL positive nuclei per field found in
dy2J mice compared to controls (p,0.04). (Figure 2).
Analysis of values as a percentage of mean wild type
values. Table S1 demonstrates how the outcome measures in
dy2J mice vary in respect to wild type mice measures at 30–33
weeks of age. The previous results are depicted as a percentage of
the wild type value and show decreased body/organ weights,
activity levels, grip strength and specific force measures.
Phenotypic Differences Between dy2J Mice Treated with
Omigapil and Untreated dy2J Mice
At 30–33 weeks of age, there were no significant differences in
body weights, organ weights or grip strength among the three dy2J
homozygous groups with different omigapil dosages and vehicle
treatment (Table 3). Outcome measures for controls and vehicle
and treated dy2J mice at 22–25 weeks of age and 26–29 weeks of
age are shown in Tables S2 and S3.
Behavioral assessments. At the completion of the trial, dy2J
mice treated with 0.1 mg/kg omigapil showed significantly more
movement time and less rest time when compared to vehicle
Omigapil Treatment in dy2J Mice
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treated dy2J mice. There were no significant differences seen in
other parameters, although the values for the dy2J mice were
decreased for all parameters and only showed slight improvements
with omigapil treatment.
Functional assessments. At the completion of the trial, dy2J
mice treated with 0.1 mg/kg and 1 mg/kg omigapil showed
significantly increased respiratory rates compared to vehicle
treated dy2J mice. Respiratory rates for omigapil treated mice
were similar to control mice. Treatment with omigapil did not
alter cardiac function or in vitro force testing.
Longitudinal changes in selected outcome measures are shown
in Figure S1. Individual measures for selected outcomes and age of
measurement are shown in Figure S2.
Histological assessment. In the gastrocnemius, the dy2J
group treated with 0.1 mg/kg omigapil showed significantly
decreased fibrosis compared to the vehicle treated dy2J mice.
dy2J mice treated with 1 and 0.1 mg/kg omigapil showed
significantly decreased fibrosis in the diaphragm compared to
the vehicle and the 0.1 mg/kg omigapil treated dy2J mice were
also significantly decreased compared to the 1 mg/kg treatment
group. Both 1 and 0.1 mg/kg omigapil treatment led to a
significant decrease in the percent area of degenerating fibers and
percent centralized nuclei per fiber in the gastrocnemius compared
to vehicle treated mice. (Figure 1).
TUNEL assay. There was a decrease in the percent TUNEL
positive nuclei per field in omigapil treated dy2J mice. The
differences between vehicle and each of the treatments are
significant alone, but when adjusted for multiple comparisons by
comparing each group to the others, they do not reach
significance. (Figure 2).
Analysis of values as a percentage of mean wild type
values. Table S1 demonstrates how the outcome measures in
dy2J mice vary in respect to wild type mice measures at the end of
the trial. Consistent with the data analysis, the dy2J mice treated
with 0.1 mg/kg/day omigapil showed significantly less decreased
respiratory rate and less increased fibrosis in both gastrocnemius
and diaphragm when compared to vehicle treated mice. The dy2J
mice treated with 1 mg/kg/day omigapil also showed significantly
less decreased respiratory rate when compared to vehicle treated
mice.
Discussion
This study provides phenotypic data on the dy2J mouse model of
congenital muscular dystrophy and demonstrates effective out-
come measures for preclinical trials. dy2J mice demonstrated
decreased body weights and poor growth, decreased forelimb grip
strength, decreased respiratory rates and increased fibrosis in the
gastrocnemius and diaphragm compared to control mice.
Apoptosis is one mechanism shown to be involved in the
pathogenesis of MDC1A. [7–10] Omigapil, an inhibitor of the
GAPDH-Siah1-mediated apoptosis, was found to be effective in
the dyW mouse model. [10] This study also demonstrated
significant improvement in functional and histological measures
in the dy2J model after therapy with the omigapil (0.1 mg/kg),
providing further support for clinical trials of omigapil in
congenital muscular dystrophy.
Due to the mild phenotype of the dy2J model, histological
evaluation of fibrosis provided the strongest evidence for a
beneficial effect of omigapil. Omigapil significantly reduced the
percent of fibrosis in the gastrocnemius and the diaphragm. Erb
et al. (2009) studied omigapil in the dyW/dyW mouse model of
congenital muscular dystrophy. [10] dyW mice have a more severe
phenotype than the dy2J mice and early death. Erb et al. (2009)
demonstrated decreased fibrosis of the triceps brachii with
0.1 mg/kg omigapil dosing. In our study, both the gastrocnemius
and diaphragm demonstrated significantly decreased fibrosis in the
0.1 mg/kg omigapil group and just the diaphragm in the 1 mg/kg
group. Decreased fibrosis is likely indicative of decreased muscle
cell apoptosis due to omigapil therapy. In support of this, we also
Table 1. Baseline outcome measures for BL6 control and dy2J mice at 12–15 weeks of age show decreased body weights, forelimb
grip strength, vertical activity and increased heart rates in dy2J mice.
Measurement BL6 dy
2J
P-value
N Mean ± SD N Mean ± SD
%FS 6 3461 10 3361 0.1421
%EF 6 6361 10 6361 0.9125
Heart rate (BPM) 6 459623 10 524618 ,0.001
PA velocity (mm/s) 6 757672 10 741659 0.6365
Ao velocity (mm/s) 6 10586101 10 1070668 0.7868
E/A ratio 6 1.7860.06 9 1.7060.11 0.1060
Horizontal activity* 6 15106564; 1578 (712–2390)21 12866247; 1213 (954–1784) 0.2938
Total distance (cm)* 6 4316219; 389 (156–811) 21 3386144; 304 (115–671) 0.2678
Movement time(second)* 6 52627; 48 (19–99) 21 47619; 45 (18–92) 0.7483
Rest time(second)* 6 548627; 553 (501–581) 21 553619; 555 (508–582) 0.7263
Vertical activity* 6 2769; 25 (16–41) 21 664; 5 (0–15) 0.0002
GSM forelimb (KGF) 6 0.11260.014 21 0.07360.010 ,0.001
Normalized GSM forelimb (KGF/kg) 6 4.51960.871 21 3.97360.664 0.1095
Body weight (g) 6 25.163.7 21 18.661.8 ,0.001
*Non-parametric comparison of medians; data expressed as mean 6 SD; median (range).
Abbreviations: %FS – percent fractional shortening, %EF- percent ejection fraction, BPM- beats per minute, Om – omigapil, SD – standard deviation, PA – pulmonary
artery, Ao – aortic, E/A – ratio of mitral valve E and A wave velocities, GSM – grip strength meter, KGF – kilogram-force.
doi:10.1371/journal.pone.0065468.t001
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found decreased apoptosis in the tibialis anterior muscle of
omigapil treated dy2J mice. (Figure 2) Apoptosis is a known
pathologic pathway in congenital muscular dystrophy patients. [4].
Erb et al. (2009) also measured manual recordings of mouse
activity in a new cage environment and showed omigapil treated
mice had significantly increased activity compared to vehicle
treated mice at 5–6 weeks of age. This significance was lost at 10
weeks of age, but a trend continued. In the milder phenotype of
the dy2J mice, this study showed significantly increased movement
times and decreased rest times in mice treated with 0.1 mg/kg. So,
in the more severe model, an improvement was demonstrated
early and lost over time, while in this milder phenotypic model, the
improvements were beginning to show and likely require a longer
treatment period to fully develop.
Erb et al. (2009) also presented histological data showing the
muscle fiber size distribution normalized by reducing the
proportion of small caliber and increasing the proportion of large
caliber muscle fibers in the triceps brachii of dyW mice treated with
0.1 mg/kg omigapil. The current study did not measure fiber size,
but we did see a significant decrease in percent centralized nuclei
per fiber (a measure of total regeneration) between omigapil
treatment and vehicle control groups in the gastrocnemius. We
also showed significantly decreased percent in areas of degener-
ating fibers in the gastrocnemius in the omigapil treated mice. A
decrease in degeneration leads to less regeneration and preserva-
tion of larger fibers, a similar observation as reported by Erb et al.
dy2J mice showed significantly increased respiratory rates in
omigapil treated mice at the end of the trial compared to vehicle
treated. These increased rates were similar to wild type controls.
This in vivo functional measure could reflect improved diaphragm
function. This finding is quite important since clinically many of
the affected patients suffer significant respiratory insufficiency and
this is a leading cause of death. Any effective therapy needs to
demonstrate improvements in respiratory function and these
changes support a putative role for omigapil.
Table 2. Outcome measures for BL6 control and vehicle treated dy2J mice at 30–33 weeks of age show decreased activity, in vitro
force and fibrosis.
Measurement BL6 Control dy
2J vehicle P-value
N Mean ± SD N Mean ± SD
%FS 6 3461 7 3461 0.4952
%EF 6 6362 7 6462 0.2857
Heart rate (BPM) 6 47569 7 548618 ,0.001
PA velocity (mm/s) 6 723650 7 724688 0.8109
Ao velocity (mm/s) 6 1039679 7 9246105 0.0514
E/A ratio 6 1.6560.07 7 1.6660.05 0.7022
Horizontal activity* 6 14366653; 1661 (598–2046) 7 6196111; 562 (487–748) 0.0321
Total distance (cm)* 6 3286208; 387 (62–539) 7 63620; 70 (34–84) 0.0152
Movement time(second)* 6 38623; 44 (8–59) 7 963; 10 (5–13) 0.0179
Rest time(second)* 6 562623; 557 (541–592) 7 59163; 590 (587–595) 0.0179
Vertical activity* 6 1768; 20 (6–25) 7 060; 0 (0–0) 0.0011
GSM forelimb (KGF) 6 0.13260.014 7 0.09060.010 ,0.001
Normalized GSM forelimb (KGF/kg) 6 4.44061.205 7 4.23960.483 0.6917
Body weight (g) 6 31.267.0 7 21.462.6 0.0052
Respiratory rate (bpm) 6 40566 7 371618 0.0010
Heart weight/BW 6 3.7860.60 6 4.3460.36 0.0757
Spleen weight/BW 6 3.2061.18 7 3.3460.55 0.7785
Gastroc Weight/BW 6 4.3560.56 7 2.2560.47 ,0.001
Soleus weight/BW 6 0.3360.04 7 0.2460.10 0.0655
TA weight/BW 6 1.5660.23 6 1.0860.32 0.0128
Hindlimb maximal force 6 414671 7 223631 ,0.001
Hindlimb specific force 6 255632 7 184628 0.0013
% fibrosis – gastroc 6 2.160.2 7 20.662.6 ,0.001
% fibrosis - diaphragm 6 8.461.8 7 14.760.7 ,0.001
% area with degenerating fibers – gastroc 6 060 7 10.163.10 ,0.001
% Centralized nuclei fiber-gastroc* 6 2.861.0; 2.5 (1.9–4.6) 7 36.463.2; 38.0 (30.5–39.5) 0.0027
% Centralized nuclei fiber-diaphragm * 6 2.960.3; 3.0 (2.5–3.2) 7 13.661.5; 13.3 (12.0–16.6) 0.0027
% apoptosis nuclei per field* 4 0.760.7; 0.7 (0.4–1.0) 3 36.264.1; 38.0 (31.5–39.2) 0.0339
*Non-parametric comparison of medians; data expressed as mean 6 SD; median (range).
Abbreviations: %FS – percent fractional shortening, %EF- percent ejection fraction, BPM- beats per minute, bpm – breaths per minute, SD – standard deviation, PA –
pulmonary artery, AO – aortic, E/A – ratio of mitral valve E and A wave velocities, GSM – grip strength meter, BW- body weight, Gastroc – gastrocnemius, TA – tibialis
anterior, KGF – kilogram-force.
doi:10.1371/journal.pone.0065468.t002
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Echocardiographic analysis found increased heart rates in dy2J
mice. This is a consistent finding in other dystrophic mouse models
and could reflect imbalances in the sympathetic nervous system.
[14] The increased heart rate does not appear to be a
compensatory mechanism for decreased heart function, since the
measurements of systolic function are normal. There was a trend
towards normal heart rates in dy2J mice treated with 0.1 mg/kg
omigapil, but this did not reach significance.
Of interest, some of the functional data and the decreased
fibrosis support a benefit of the lower dosing omigapil at 0.1 mg/
kg compared to the higher dose at 1 mg/kg. While some of the
body weight and activity data from Erb et al. (2009) support
increased benefits from a higher dose of 1 mg/kg, Waldmeier
et al. (2000) published dose response curves in other mouse models
that showed benefits were lost above 1 mg/kg/day of omigapil.
[19] Our study supports these findings, even showing that
diaphragm fibrosis was significantly decreased in 0.1 mg/kg
compared to 1 mg/kg omigapil dosing. This important preclinical
observation might aid in the selection of drug dosing for clinical
trials.
There were some limitations in this study. This study did not
look at forelimb muscle force or histology. Due to the significant
demyelination of the hindlimb and paralysis, hindlimb muscle
changes were likely affected by mechanisms other than just
laminin defects and may not reflect improvements seen in other
muscle groups. This study also included a 10 week treatment
Figure 1. Histological analysis of gastrocnemius and diaphragm with H&E (top two rows) and gastrocnemius with picrosirius red
(bottom row) show increased fibrosis and centralized nuclei in dy2J mice. BL6 control mice are shown in column A. dy2J mice treated with
0.1 mg/kg omigapil (Column B) showed markedly less fibrosis compared to dy2J mice treated with 1 mg/kg omigapil (Column C) or vehicle (Column
D).
doi:10.1371/journal.pone.0065468.g001
Figure 2. Apoptosis analysis of frozen tibialis anterior muscle with TUNEL assay on vehicle (A), Omigapil 0.1 mg/kg (B), Omigapil
1 mg/kg (C) treated dy2J and BL6 control (D) groups show vehicle treated dy2J mice had significantly more apoptosis than BL6
control (A, D, F; *P,0.05). Both Omigapil treated groups showed less apoptosis than vehicle treated group although statistically not different (A-
C, F). BL6 slide treated with TACS-Nuclease was used as positive control (E).
doi:10.1371/journal.pone.0065468.g002
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period, followed by a 4 week washout period and then 3.5 weeks of
retreatment. The purpose of this design was to uncover any
significant drug effect with a washout period and if this effect was
recoverable with retreatment. There were no significant differ-
ences shown in outcome measures after the initial 10 weeks of
treatment (Table S2) or after the 4 week washout period (Table
S3). This is potentially related to factors including minimal disease
progression, variability in outcome measures and incomplete
penetrance. As shown, significant findings were seen after the
completion of 3.5 weeks of retreatment (Table 3). As noted, the
major findings of the study were histological with trends towards
functional improvements, but a longer treatment period will be
required in future studies to reach significance.
In conclusion, this study shows decreased fibrosis and improved
respiratory rate in dy2J mice treated with 0.1 mg/kg omigapil. We
provide phenotypic data to further characterize the dy2J model for
future preclinical trials. These findings support a putative role for
omigapil in the treatment of congenital muscular dystrophy.
Table 3. Outcome measures for 30–33 week old omigapil and vehicle treated dy2J mice after 17.5 weeks show significant
improvements in respiratory rate and fibrosis in dy2J 0.1 mg/kg omigapil treated mice.
Measurement dy
2J vehicle dy2J Omigapil 0.1 mg dy2J Omigapil 1 mg Significantly different mean/medians
N Mean ± SD N Mean ± SD N Mean ± SD
%FS 7 3461 7 3363 7 3461 NONE
%EF 7 6462 7 6362 7 6462 NONE
Heart rate (BPM) 7 548618 7 527634 7 563663 NONE
PA velocity (mm/s) 7 724688 7 694674 7 687693 NONE
Ao velocity (mm/s) 7 9246105 7 9176106 7 942673 NONE
E/A ratio 7 1.6660.05 7 1.6860.11 5 1.8160.15 NONE
Horizontal activity* 7 6196111; 562 (487–748)7 9066290; 778
(682–1332)
7 6966258; 802 (203–
1285)
NONE
Total distance (cm)* 7 63620; 70 (34–84) 7 1636110; 112
(69–324)
7 128697; 115 (15–296) NONE
Movement time(second)* 7 963; 10 (5–13) 7 23614; 17 (11–45) 7 19614; 18 (2–43) Vehicle vs. 0.1 mg (p = 0.026)
Rest time(second)* 7 59163; 590 (587–595) 7 577614; 583
(555–589)
7 581614; 582 (557–598) Vehicle vs. 0.1 mg (p = 0.026)
Vertical activity* 7 060; 0 (0–0) 7 0.160.4; 0 (0–1) 7 060; 0 (0–0) NONE
GSM forelimb (KGF) 7 0.09060.010 7 0.08460.012 7 0.08660.010 NONE
Normalized GSM forelimb
(KGF/kg)
7 4.23960.483 7 4.31860.603 7 4.32160.621 NONE
Body weight (g) 7 21.462.6 7 19.562.3 7 20.363.2 NONE
Respiratory rate (bpm) 7 371618 7 396611 7 402619 Vehicle vs. 0.1 mg (p = 0.026)
Vehicle vs. 1 mg (p = 0.006)
Heart weight/BW 6 4.3460.36 7 4.3860.40 7 4.5160.53 NONE
Spleen weight/BW 7 3.3460.55 7 3.1360.63 7 3.2260.62 NONE
Gastroc Weight/BW 7 2.2560.47 7 2.1960.58 7 2.1760.48 NONE
Soleus weight/BW 7 0.2460.10 7 0.2860.05 7 0.3060.07 NONE
TA weight/BW 6 1.0860.32 7 1.2860.18 7 1.2860.27 NONE
Hindlimb maximal force 7 223631 7 220641 7 223646 NONE
Hindlimb specific force 7 184628 7 193627 7 177622 NONE
% fibrosis – gastroc 7 20.662.6 7 16.462.0 7 17.263.3 Vehicle vs. 0.1 mg (p = 0.030)
% fibrosis - diaphragm 7 14.760.7 7 9.461.7 7 12.262.1 Vehicle vs. 0.1 mg (p,0.001)
Vehicle vs. 1 mg (p = 0.032)
0.1 mg vs. 1 mg (p= 0.013)
% area with degenerating
fibers – gastroc.
7 10.163.1 7 3.060.7 7 5.863.8 Vehicle vs. 0.1 mg (p = 0.001)
Vehicle vs. 1 mg (p = 0.037)
% Centralized nuclei
fiber-gastroc*
7 36.463.2; 38.0 (30.5–
39.5)
7 28.263.0; 27.3 (25.3–
33.4)
7 29.064.9; 27.6 (22.7–
36.1)
Vehicle vs. 0.1 mg (p = 0.0120)
Vehicle vs. 1 mg (p = 0.0376)
% Centralized nuclei
fiber-diaphragm*
7 13.661.5; 13.3 (12.0–
16.6)
6 13.261.9; 12.9 (11.1–
16.5)
7 12.861.5; 13.1 (10.9–
14.9)
NONE
% apoptosis nuclei per field* 3 36.364.1; 38.0 (31.5–
39.2)
4 5.961.1; 5.6 (4.7–7.5) 4 4.561.7; 4.3 (2.9–6.9) NONE
*Non-parametric comparison of medians; data expressed as mean 6 SD; median (range).
Abbreviations: %FS – percent fractional shortening, %EF- percent ejection fraction, BPM- beats per minute, bpm – breaths per minute, SD – standard deviation, PA –
pulmonary artery, AO – aortic, E/A – ratio of mitral valve E and A wave velocities, GSM – grip strength meter, BW- body weight, Gastroc – gastrocnemius, TA – tibialis
anterior, KGF.
doi:10.1371/journal.pone.0065468.t003
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Supporting Information
Figure S1 Longitudinal functional test data for groups
with mean and standard deviation for BL6 and dy2J
(vehicle, 0.1 mg/kg omigapil and 1 mg/kg omigapil)
mice across the protocol time points: baseline; after 10
weeks of treatment with omigapil; after 4 week washout
period; and after 3.5 weeks of retreatment with
omigapil.
(TIF)
Figure S2 Individual mouse functional test data and age
measured for BL6 and dy2J (vehicle, 0.1 mg/kg omiga-
pil, 1 mg/kg omigapil) mice during the main protocol
time periods: baseline; after 10 weeks of treatment with
omigapil; after 4 week washout period; and after 3.5
weeks of retreatment with omigapil.
(TIF)
Table S1 Analysis of outcome measure values as a
percentage of mean wild type values in 30-33 week old
omigapil and vehicle treated dy2J mice showing signifi-
cance in respiratory rate and fibrosis.
(DOCX)
Table S2 Outcome measures for BL6 control, vehicle
and Omigapil treated dy2J mice at 22-25 weeks of age
when mice were treated for 10 weeks.
(DOCX)
Table S3 Outcome measures for BL6 control, vehicle
and Omigapil treated dy2J mice at 26-29 weeks of age
when mice stopped treatment for 4 weeks.
(DOCX)
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